AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30788809 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP of 7 cmH2O (group P)
Number of subjects: 67
Study 30788809 — intervention group
Group type: COMPARATOR
Intervention: Zero end-expiratory pressure (group Z)
Number of subjects: 67
Study 29292310 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored cessation intervention for smokers (Ps/Cs)
Number of subjects: 110
Study 29292310 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 110
Study 26814235 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure management (target systolic blood pressure <140 mm Hg)
Number of subjects: 2653
Study 26814235 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based blood pressure management (systolic blood pressure <180 mm Hg)
Number of subjects: 2653
Study 24788342 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD 1 COPD
Number of subjects: 208
Study 24788342 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD 2 COPD
Number of subjects: 208
Study 24788342 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD 1 and 2 COPD
Number of subjects: 208
Study 23171095 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 881
Study 23171095 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 881
Study 20358390 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical SLS 0.25%
Number of subjects: 8
Study 20358390 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical SLS 0.5%
Number of subjects: 8
Study 20358390 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical SLS 1%
Number of subjects: 8
Study 20358390 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical SLS 2%
Number of subjects: 8
Study 20358390 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 8
Study 20358390 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin 1%
Number of subjects: 8
Study 17965059 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride 100 mg three times daily
Number of subjects: 1170
Study 17965059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1170
Study 15837826 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 28356
Study 12578875 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum soluble ST2 levels measured at trial enrollment and 2 weeks after enrollment
Number of subjects: 161
Study 12578875 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BNP levels
Number of subjects: 161
Study 12578875 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ProANP levels
Number of subjects: 161
Study 12578875 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in ST2 levels
Number of subjects: 161
Study 11347858 — intervention group
Group type: EXPERIMENTAL
Intervention: lacidipine 4 mg o.d. (increased to 6 mg if needed)
Number of subjects: 62
Study 11347858 — intervention group
Group type: COMPARATOR
Intervention: amlodipine 5 mg o.d. (increased to 10 mg if needed)
Number of subjects: 62
Study 11347858 — intervention group
Group type: EXPERIMENTAL
Intervention: lacidipine 6 mg (for patients requiring dose increase)
Number of subjects: 62
Study 11347858 — intervention group
Group type: COMPARATOR
Intervention: amlodipine 10 mg (for patients requiring dose increase)
Number of subjects: 62
Study 11347858 — intervention group
Group type: EXPERIMENTAL
Intervention: lacidipine
Number of subjects: 62
Study 11347858 — intervention group
Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 62
Study 8973988 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day 17 beta-estradiol transdermal delivery system (TDS) applied to the abdomen
Number of subjects: 18
Study 8973988 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day 17 beta-estradiol transdermal delivery system (TDS) applied to the buttocks
Number of subjects: 18
Study 8973988 — intervention group
Group type: EXPERIMENTAL
Intervention: Early TDS replacement on day 17
Number of subjects: 18
Study 8973988 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated TDS applications to the buttocks
Number of subjects: 18
Study 1316059 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg lomefloxacin orally once daily (n = 259)
Number of subjects: 522
Study 1316059 — intervention group
Group type: COMPARATOR
Intervention: 250 mg cefaclor every 8 hours (n = 263)
Number of subjects: 522
Study 1316059 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg lomefloxacin
Number of subjects: 522
Study 1316059 — intervention group
Group type: COMPARATOR
Intervention: 250 mg cefaclor
Number of subjects: 522
Study 3909840 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptanaesthesia
Number of subjects: 51
Study 3909840 — intervention group
Group type: COMPARATOR
Intervention: Continuous thoracic epidural anesthesia
Number of subjects: 51
Study 31496390 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual task paradigm (simultaneous working memory task)
Number of subjects: 0
Study 31496390 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus on accuracy in decision making
Number of subjects: 0
Study 31496390 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus on speed in decision making
Number of subjects: 0
Study 31496390 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulating intertrial interval (more time to learn from feedback)
Number of subjects: 0
Study 29438199 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc intensified ART (Arm2: abacavir-lamivudine and darunavir/ritonavir/maraviroc)
Number of subjects: 60
Study 29438199 — intervention group
Group type: COMPARATOR
Intervention: Standard ART (Arm1: tenofovir-emtricitabine and atazanavir/ritonavir)
Number of subjects: 60
Study 29438199 — intervention group
Group type: COMPARATOR
Intervention: Standard ART (Arm1)
Number of subjects: 60
Study 29438199 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc intensified ART (Arm2)
Number of subjects: 60
Study 27210035 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 1186
Study 24912466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratings based on entire therapy sessions
Number of subjects: 84
Study 24912466 — intervention group
Group type: COMPARATOR
Intervention: Ratings based on session segments (middle third of entire sessions)
Number of subjects: 84
Study 22391940 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB exposure in a commercial tanning bed (UVB/UVA ratio 1.8‐2.0%)
Number of subjects: 20
Study 22391940 — intervention group
Group type: COMPARATOR
Intervention: Placebo tanning bed without UVB
Number of subjects: 20
Study 22391940 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB exposure in a commercial tanning bed
Number of subjects: 20
Study 20364565 — intervention group
Group type: EXPERIMENTAL
Intervention: Meronem
Number of subjects: 16
Study 20364565 — intervention group
Group type: EXPERIMENTAL
Intervention: Mero
Number of subjects: 16
Study 18246429 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs: olanzapine, quetiapine, risperidone, ziprasidone)
Number of subjects: 1121
Study 18246429 — intervention group
Group type: COMPARATOR
Intervention: First-generation antipsychotic (FGA: perphenazine)
Number of subjects: 1121
Study 15766337 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose regimen of diamorphine 0.4 mg in hyperbaric bupivacaine 0.5% 2.4 ml
Number of subjects: 100
Study 15766337 — intervention group
Group type: COMPARATOR
Intervention: Adjusted dose regimen of diamorphine 0.4 mg in hyperbaric bupivacaine 0.5%
Number of subjects: 100
Study 12527943 — intervention group
Group type: EXPERIMENTAL
Intervention: BB-10010 with dose-intensified BEMOP/CA chemotherapy
Number of subjects: 13
Study 12527943 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 13
Study 11029510 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (letrozole, anastrozole, exemestane)
Number of subjects: 0
Study 9165692 — intervention group
Group type: EXPERIMENTAL
Intervention: BY841 (50 mg or 100 mg twice daily)
Number of subjects: 0
Study 9165692 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (standard dose)
Number of subjects: 0
Study 9165692 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 0
Study 10148879 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled administration of fentanyl (n=37)
Number of subjects: 80
Study 10148879 — intervention group
Group type: COMPARATOR
Intervention: Nurse administration on demand (n=43)
Number of subjects: 80
Study 2579257 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil
Number of subjects: 305
Study 2579257 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil plus doxorubicin (FA)
Number of subjects: 305
Study 2579257 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil plus doxorubicin plus mitomycin (FAM)
Number of subjects: 305
Study 30579673 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention to reduce sodium intake
Number of subjects: 0
Study 30579673 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 30303108 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular point-of-care testing for C trachomatis and N gonorrhoeae
Number of subjects: 455
Study 30303108 — intervention group
Group type: COMPARATOR
Intervention: Standard care (routine laboratory-based testing)
Number of subjects: 455
Study 26795538 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailings and a coaching call intervention
Number of subjects: 244
Study 26795538 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 244
Study 25133799 — intervention group
Group type: EXPERIMENTAL
Intervention: IMID training
Number of subjects: 36
Study 25133799 — intervention group
Group type: EXPERIMENTAL
Intervention: IMID training and OSS combined
Number of subjects: 36
Study 25133799 — intervention group
Group type: COMPARATOR
Intervention: OSS
Number of subjects: 36
Study 22444188 — intervention group
Group type: EXPERIMENTAL
Intervention: μ-opioid agonist alfentanil
Number of subjects: 224
Study 22444188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 20047672 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini booster (two telephone calls one month apart)
Number of subjects: 600
Study 20047672 — intervention group
Group type: EXPERIMENTAL
Intervention: Full booster (face-to-face meeting with facilitator at the same intervals)
Number of subjects: 600
Study 20047672 — intervention group
Group type: COMPARATOR
Intervention: No booster (control group)
Number of subjects: 600
Study 17209211 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation at 4 mg/d for high-risk women and 0.4 mg/d for others
Number of subjects: 0
Study 17209211 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid fortification mandated in the United States and some other countries
Number of subjects: 0
Study 18569356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (5 a Day, the Rio Grande Way website)
Number of subjects: 755
Study 18569356 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 755
Study 18569356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (website use)
Number of subjects: 755
Study 15086228 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid weaning from external ventricular drainage (EVD) within 24 hours with immediate closure of the EVD
Number of subjects: 81
Study 15086228 — intervention group
Group type: COMPARATOR
Intervention: Gradual weaning from external ventricular drainage (EVD) over a 96-hour period
Number of subjects: 81
Study 12182055 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine suppressive therapy
Number of subjects: 4
Study 12182055 — intervention group
Group type: COMPARATOR
Intervention: L-thyroxine replacement therapy
Number of subjects: 4
Study 9408856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine (tablet)
Number of subjects: 18
Study 9408856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine (capsule)
Number of subjects: 18
Study 9408856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine (intravenous infusion)
Number of subjects: 18
Study 8358281 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Detector
Number of subjects: 1842
Study 8358281 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloscreen Self-Test
Number of subjects: 1842
Study 8358281 — intervention group
Group type: COMPARATOR
Intervention: Haemoccult
Number of subjects: 1842
Study 8358281 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restriction
Number of subjects: 1842
Study 8358281 — intervention group
Group type: EXPERIMENTAL
Intervention: No dietary restriction
Number of subjects: 1842
Study 3302144 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise
Number of subjects: 76
Study 3302144 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 76
Study 3302144 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 76
Study 3302144 — intervention group
Group type: COMPARATOR
Intervention: Education (control)
Number of subjects: 76
Study 31718583 — intervention group
Group type: EXPERIMENTAL
Intervention: HiBalance program (balance training program emphasizing challenging exercises and dual-tasking)
Number of subjects: 100
Study 31718583 — intervention group
Group type: COMPARATOR
Intervention: HiCommunication program (active control targeting speech and communication)
Number of subjects: 100
Study 31718583 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (HiBalance and HiCommunication)
Number of subjects: 100
Study 28081304 — intervention group
Group type: EXPERIMENTAL
Intervention: ACpT (4 cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 followed by 4 cycles of paclitaxel 175 mg/m2)
Number of subjects: 1060
Study 28081304 — intervention group
Group type: EXPERIMENTAL
Intervention: ACdT (4 cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 followed by 4 cycles of docetaxel 75 mg/m2)
Number of subjects: 1060
Study 28081304 — intervention group
Group type: COMPARATOR
Intervention: PTx (8 cycles of paclitaxel every 3 weeks)
Number of subjects: 1060
Study 28081304 — intervention group
Group type: COMPARATOR
Intervention: DTx (8 cycles of docetaxel every 3 weeks)
Number of subjects: 1060
Study 25458980 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-flow nasal cannula oxygen at 15 L/minute
Number of subjects: 77
Study 25458980 — intervention group
Group type: COMPARATOR
Intervention: Lower-flow nasal cannula oxygen at 6 L/minute
Number of subjects: 77
Study 23896732 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based interactive decision aid
Number of subjects: 1893
Study 23896732 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-based decision aid
Number of subjects: 1893
Study 23896732 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1893
Study 23896732 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1893
Study 21849400 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held preoperative compact imager (POCI)
Number of subjects: 162
Study 21849400 — intervention group
Group type: COMPARATOR
Intervention: Conventional lymphoscintigraphy
Number of subjects: 162
Study 19414676 — intervention group
Group type: EXPERIMENTAL
Intervention: RRS-82 (relapse-related molecular signature) identified through genome-wide expression profiling analysis
Number of subjects: 117
Study 19414676 — intervention group
Group type: EXPERIMENTAL
Intervention: RRS-82 validated in an independent cohort of 30 stage I patients
Number of subjects: 117
Study 19414676 — intervention group
Group type: EXPERIMENTAL
Intervention: RRS-82 validated using Duke data set
Number of subjects: 117
Study 19414676 — intervention group
Group type: EXPERIMENTAL
Intervention: RRS-82 validated using another data set from the Director's Challenge Consortium
Number of subjects: 117
Study 17869291 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 0
Study 17869291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17869291 — intervention group
Group type: EXPERIMENTAL
Intervention: Erection Quality Scale
Number of subjects: 0
Study 16926937 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive primary care outreach interventions
Number of subjects: 14911
Study 12482164 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrostep® (norethindrone acetate/ethinyl estradiol)
Number of subjects: 591
Study 12482164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 591
Study 9579448 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 50 microg/day
Number of subjects: 45
Study 9579448 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tamoxifen 20 mg/day
Number of subjects: 45
Study 9579448 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 45
Study 7648962 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Intralipid (nine patients)
Number of subjects: 27
Study 7648962 — intervention group
Group type: EXPERIMENTAL
Intervention: 26.7% Glucose (nine patients)
Number of subjects: 27
Study 7648962 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control group)
Number of subjects: 27
Study 2668227 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Suppressor Unit (cranial electrotherapy stimulator)
Number of subjects: 100
Study 2668227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 52007 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 12
Study 31306800 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 12378
Study 31306800 — intervention group
Group type: COMPARATOR
Intervention: Nonentecavir HBV nucleos(t)ide analogue
Number of subjects: 12378
Study 31306800 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Entecavir and Nonentecavir)
Number of subjects: 12378
Study 31546856 — intervention group
Group type: EXPERIMENTAL
Intervention: iPad-enhanced aerobic exercise
Number of subjects: 27
Study 31546856 — intervention group
Group type: COMPARATOR
Intervention: aerobic exercise-only
Number of subjects: 27
Study 28304219 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR (transcatheter aortic-valve replacement)
Number of subjects: 1746
Study 28304219 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic-valve replacement
Number of subjects: 1746
Study 28304219 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 1746
Study 28304219 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 1746
Study 28304219 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TAVR and Surgery
Number of subjects: 1746
Study 24690383 — intervention group
Group type: EXPERIMENTAL
Intervention: SeqA60% (60% of 1RM)
Number of subjects: 13
Study 24690383 — intervention group
Group type: EXPERIMENTAL
Intervention: SeqA80% (80% of 1RM)
Number of subjects: 13
Study 24690383 — intervention group
Group type: EXPERIMENTAL
Intervention: SeqB60% (60% of 1RM)
Number of subjects: 13
Study 24690383 — intervention group
Group type: EXPERIMENTAL
Intervention: SeqB80% (80% of 1RM)
Number of subjects: 13
Study 23881301 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected kidneys (ARFI imaging)
Number of subjects: 28
Study 23881301 — intervention group
Group type: COMPARATOR
Intervention: Contralateral kidneys (ARFI imaging)
Number of subjects: 28
Study 23881301 — intervention group
Group type: COMPARATOR
Intervention: Healthy kidneys (ARFI imaging)
Number of subjects: 28
Study 23881301 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected kidneys with secondary reflux (ARFI imaging)
Number of subjects: 28
Study 21899210 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone i.m. (BSP 2 mg and BDP 5 mg)
Number of subjects: 10
Study 19853726 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 25928
Study 19853726 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 25928
Study 19853726 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 25928
Study 19853726 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 25928
Study 19853726 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 25928
Study 19853726 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 25928
Study 19853726 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 25928
Study 19853726 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 25928
Study 19853726 — intervention group
Group type: COMPARATOR
Intervention: Reboxetine
Number of subjects: 25928
Study 16717333 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.0 MAC (BIS 40-50)
Number of subjects: 44
Study 16717333 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 1.0 MAC (BIS 40-50)
Number of subjects: 44
Study 16717333 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.2 MAC (BIS 40-50)
Number of subjects: 44
Study 16717333 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 1.6 MAC (BIS 20-30)
Number of subjects: 44
Study 16717333 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.8 MAC (BIS 20-30)
Number of subjects: 44
Study 29932416 — intervention group
Group type: EXPERIMENTAL
Intervention: Bretol® patch (test drug)
Number of subjects: 27
Study 29932416 — intervention group
Group type: COMPARATOR
Intervention: Hokunalin® patch (reference drug)
Number of subjects: 27
Study 11810114 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV)
Number of subjects: 354
Study 9131723 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (up to 450 mg)
Number of subjects: 25
Study 9131723 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine (up to 450 mg)
Number of subjects: 25
Study 9131723 — intervention group
Group type: COMPARATOR
Intervention: Control group (13 matched healthy persons)
Number of subjects: 25
Study 7703598 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (1 g/kg body wt)
Number of subjects: 13
Study 7703598 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (1 g/kg body wt)
Number of subjects: 13
Study 7703598 — intervention group
Group type: COMPARATOR
Intervention: Glucose and Fructose
Number of subjects: 13
Study 3299116 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (up to 4 micrograms/day)
Number of subjects: 14